Physician profile
Taher Elsdai
NPI 1457616419
$1,265.33
in general payments reported to CMS, 2019-2025
21 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.76 · 2020: $88.66 · 2021: $194 · 2022: $345 · 2023: $102 · 2024: $123 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.80 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $352.63 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $345.22 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $120.07 | 2022-2025 | |
| Dexcom, INC. | $66.13 | 2021-2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $41.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.32 | 2022 | |
| Medtronic Minimed, INC. | $36.60 | 2020 | |
| Amneal Pharmaceuticals LLC | $32.17 | 2021-2022 | |
| Abbott Laboratories | $30.84 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $28.73 | 2021-2022 | |
| Insulet Corporation | $28.53 | 2021 | |
| Cequr Corporation | $26.53 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.44 | 2019 | |
| Lilly USA, LLC | $15.09 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.49 | 2021 | |
| Shire North American Group INC | $12.12 | 2019 | |
| Nevro Corp. | $12.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $10.97 | 2019 | |
| Beta Bionics, INC. | $5.25 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taher Elsdai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.